date:Apr 17, 2013
ity towards two common mutations that are the ideal targets for melanoma treatment, Texas Biomed's Hareesh Nair, Ph.D., who headed the research, said in a media statement. Our results indicate that gossypin may have great therapeutic potential as a dual inhibitor of mutations called BRAFV600E kinase and CDK4, which occur in the vast majority of melanoma patients.
Nair added that his research team's findings ... open a new avenue for the generation of a novel class of compounds for the treatment